New MS drug trial targets kids: could ocrelizumab slow relapses?

NCT ID NCT04075266

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and B-cell levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

AOU Policlinico V. Emanuele - P.O G. Rodolico

Catania, Sicily, 95123, Italy
Azienda Ospedaliera Sant'Andrea

Rome, Lazio, 00189, Italy
Boston Childrens Hospital

Boston, Massachusetts, 02115, United States
Childrens National Health Center

Washington D.C., District of Columbia, 20010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego

Warsaw, 02-091, Poland
Instytut Pomnik Centrum Zdrowia Dziecka

Warsaw, 04-730, Poland
Ospedale Pediatrico Bambino Gesù

Rome, Lazio, 00165, Italy
University of Colorado Denver Childrens Hospital Rocky Mountain MS Center

Aurora, Colorado, 80045, United States
Uniwersytecki Szpital Kliniczny w Poznaniu

Późna, 60-355, Poland
Uniwersyteckie Centrum Kliniczne

Gda?sk, 80-952, Poland
Washington Universtiy school of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.